Replies to post #203623 on Amarin Corp Plc (AMRN)

[isaeed]

One word. WOW!!!

[james murphy]

Welll done

[Retiredceo]

Excellent. Thanks for this.

[jessellivermore]

dmicento

Very nice Dan....Good job...

Wow right from the horse's mouth...

I particularly like; "our reports also explore treatments’ economic value. And in this regard, our draft analysis currently suggests that Vascepa is highly cost-effective and fairly priced for the benefit it provides patients."

Thank for posting this...

":>) JL

[HerbieRay]

Thank you! Now all we need is for the Reps and advertising to get these words out to the professionals that count, and not rely on these professionals to randomly come across this information in the publication.

[rafunrafun]

D - Don't know if you want to ask a follow-up question, but I would be curious in knowing what would it take to get a grade A.

Great DD!

[Jamaalish]

Amazing response! From the VP of Communications no less! Just speculating, but if ICER is as tough and no nonsense as their reputation seems to be, and they are all about consumer protection and controlling costs and seeing themselves as a sort of guardian of the public trust, and still in the process of building their reputation, then I could see them having the attitude of a very strict professor. Like an A is for perfection, so no one gets an A, and very few A-minuses. Just a complete guess and nothing more on my part.

[Retiredceo]

Here’s the only part that bugs me and it’s not really negative.

“we have high certainty that Vascepa provides a small-to-substantial net health benefit”

They (he) probably could have worded that differently.

[studythosestocks]

Thanks for sharing. Great reporting!

[Whalatane]

Thx for sharing this
Kiwi

[alm2]

Dan
A simply brilliant job ... may I suggest that you send this to Amarin... they may want to use this letter as a nutshell summary of ICERs assessment of Vascepa
It represents an incredibly useful marketing aid
Allan

[Mellowmood77]

“In addition to assessing treatments’ clinical effectiveness, our reports also explore treatments’ economic value. And in this regard, our draft analysis currently suggests that Vascepa is highly cost-effective and fairly priced for the benefit it provides patients. “

I re-read this and it looks like the B+ rating is for clinical effectiveness and not cost effectiveness. The way it’s worded is the cost effectiveness of Vascepa is an A+?